Symbiotec Pharmalab Ltd

BSE: 544889

total announcements

544889.BO · 15 min delayed

BSECompany UpdateESG3 Sept 2026

Update on Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Symbiotec Pharmalab Ltd has intimated the BSE about the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information framed under Regulation 8(1) of SEBI PIT Regulations, which will come into effect from December 15, 2025.

Read more →📎 1 attachment

BSEInsider Trading / SASTRelated Party2 Sept 2026

Symbiotec Pharmalab Ltd

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund

Symbiotec Pharmalab Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Mirae Asset Mutual Fund.

Read more →📎 1 attachment

BSEInsider Trading / SAST1 Sept 2026

Symbiotec Pharmalab Ltd

Closure of trading window for the quarter ended June 30, 2026.

Symbiotec Pharmalab Ltd has closed its trading window for the quarter ended June 30, 2026, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain closed until 48 hours after the declaration of unaudited Financial Results.

Read more →📎 1 attachment

BSECompany UpdateRegulatory1 Sept 2026

Symbiotec Pharmalab Ltd

Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Symbiotec Pharmalab Ltd has submitted the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information as required by SEBI (Prohibition of Insider Trading) Regulations, 2015.

Read more →📎 1 attachment

BSECompany Update1 Sept 2026

Symbiotec Pharmalab Ltd

Disclosure regarding authority to determine materiality of event or information.

Symbiotec Pharmalab Ltd has disclosed the authorized personnel for determining materiality of events or information under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Read more →📎 1 attachment

BSENew Listingnew_listing1 Sept 2026

Symbiotec Pharmalab Ltd

Trading Members of the Exchange are hereby informed that effective from September 01, 2026, the Equity Shares of Symbiotec Pharmalab Ltd (Scrip Code: 544889) are listed and admitted to ....

Symbiotec Pharmalab Ltd's equity shares have been listed and admitted to trading on the BSE, effective from September 01, 2026, with scrip code 544889.